Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. human hormone
Show results for

Refine by

Human Hormone Articles & Analysis

8 news found

Alfa Chemistry Unveils New Main Product Line: Quality Assured and Ready to Ship

Alfa Chemistry Unveils New Main Product Line: Quality Assured and Ready to Ship

The company’s commitment to supplying high-quality chemicals is reflected in its extensive product line, which includes critical substances like Gibberellic Acid, Lipase, Lactic Acid, Xylan, Human Growth Hormone, and Oat β-Glucan. Each of these products stands as a testament to Alfa Chemistry’s unwavering dedication to scientific excellence and ...

ByAlfa Chemistry


FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

It can be used for the detection of clinical fluids and the monitoring of amino acids, vitamins, exogenous pharmaceuticals, hormones, human trace elements, toxic and detrimental elements, and human trace elements. ...

ByFocused Photonics Inc. (FPI)


Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

However, despite the remarkable impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin, this class of biologics has remained largely understudied and underutilized by biopharma due to low abundance, higher structural complexity, and the massive search space to map secreted proteins to ...

ByJuvena Therapeutics, inc.


Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced/metastatic breast cancer, including patients who are resistant to approved CDK4/6 inhibitors, to evaluate the safety, tolerability and pharmacokinetic profile of RGT-419B capsule. ...

ByRegor Pharmaceuticals Inc.


Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

The interim analysis will evaluate the safety and annualized height velocity of the three dose levels of LUM-201 against a standard dose of injectable recombinant human growth hormone (rhGH) in 40 subjects at six months on therapy. ...

ByLumos Pharma


Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

It is expected to combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. The Phase I clinical trial is in ...

ByRegor Pharmaceuticals Inc.


Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor`s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor`s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

It is expected to improve the safety of and combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. ...

ByRegor Pharmaceuticals Inc.


EPA Uses Cutting-Edge Technology to Evaluate Chemicals for Human Hormone Impacts

EPA is proposing to use ground-breaking tools developed in the ToxCast program to improve testing for chemicals that have the potential to disrupt hormone function in the human body. EPA uses automated chemical screening technologies to rapidly and simultaneously perform tests on thousands of chemicals and feed the results into computational models to predict ...

ByUS EPA - Environmental Protection Agency

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT